CS
CDTX

Credit Suisse’s Cidara Therapeutics CDTX Stock Holding History

Credit Suisse’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-506
Closed -$20K – 4316
2020
Q4 		$20K Buy
+506
New +$25.2K ﹤0.01% 4304
2017
Q3 		– Sell
-1,242
Closed -$186K – 4178
2017
Q2 		$186K Buy
+1,242
New +$172K ﹤0.01% 3634
2016
Q4 		– Sell
-1,004
Closed -$229K – 4096
2016
Q3 		$229K Buy
1,004
+9
+0.9% +$2.08K ﹤0.01% 3765
2016
Q2 		$205K Buy
+995
New +$241K ﹤0.01% 3863

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's CDTX Position: Q1 2021 in Review

Credit Suisse sold out of Cidara Therapeutics (CDTX) in Q1 2021, closing a stake of 506 shares — an estimated $20K sold.

Credit Suisse first reported a position in CDTX in Q2 2016 and held it in 4 quarters. The position peaked at $229K in Q3 2016. 62 funds tracked by Wall St. Rank hold CDTX as of Q1 2021.

  • Credit Suisse reported no remaining Cidara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 506 Cidara Therapeutics shares in Q1 2021, an estimated $20K.
  • Credit Suisse first reported a position in Cidara Therapeutics in Q2 2016 and held it in 4 quarters.
  • Credit Suisse's Cidara Therapeutics position peaked at $229K in Q3 2016.
  • 62 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.